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Abstract
 Background—Workers manufacturing indium-tin oxide (ITO) are at risk of elevated indium 
concentration in blood and indium lung disease, but relationships between respirable indium 
exposures and biomarkers of exposure and disease are unknown.
 Methods—For 87 (93%) current ITO workers, we determined correlations between respirable 
and plasma indium and evaluated associations between exposures and health outcomes.
 Results—Current respirable indium exposure ranged from 0.4 to 108 μg/m3 and cumulative 
respirable indium exposure from 0.4 to 923 μg-yr/m3. Plasma indium better correlated with 
cumulative (rs = 0.77) than current exposure (rs = 0.54) overall and with tenure ≥1.9 years. Higher 
cumulative respirable indium exposures were associated with more dyspnea, lower spirometric 
parameters, and higher serum biomarkers of lung disease (KL-6 and SP-D), with significant 
effects starting at 22 μg-yr/m3, reached by 46% of participants.
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 Conclusions—Plasma indium concentration reflected cumulative respirable indium exposure, 
which was associated with clinical, functional, and serum biomarkers of lung disease.
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 INTRODUCTION
Global consumption of indium has increased several-fold in recent decades, driven by 
increasing demand for indium-tin oxide (ITO) for uses such as touch screens and solar cells 
[Omae et al., 2011; USGS, 2014]. From 2003 to 2010, 10 cases of advanced lung disease 
were reported in young workers exposed to indium compounds during the production, use, 
or reclamation of ITO [Omae et al., 2011]. Indium lung disease is now recognized as a 
potentially fatal condition characterized by pulmonary alveolar proteinosis (PAP) that may 
progress to fibrosis with or without emphysema [Cummings et al., 2012]. Multiple studies 
have demonstrated an excess burden of respiratory abnormalities in ITO industry workforces 
and associations between biological exposure markers (indium concentration in blood serum 
or plasma) and health outcomes including reduced diffusing capacity, changes on chest 
imaging, and increased levels of biomarkers of interstitial lung disease such as Krebs von 
den Lungen (KL)-6 and surfactant protein (SP)-D [Chonan et al., 2007; Hamaguchi et al., 
2008; Nakano et al., 2009; Liu et al., 2012; Choi et al., 2013; Cummings et al., 2013]. In 
Japan, a serum indium concentration of 3 μg/L is now used as a threshold for consideration 
of work restrictions [MHLW, 2010].
Despite the use of serum or plasma indium concentration as an exposure metric in 
epidemiologic studies and as a clinical tool for risk stratification, little is known about the 
relationship between serum or plasma indium concentration and workplace exposures. 
Perhaps even less is known about how health effects relate to workplace exposures because 
few published studies have included both a medical component and an environmental 
assessment of the workplace. In a small study of current and former workers at an indium 
ingot production facility, plasma indium concentrations were not correlated with airborne 
indium, and plasma indium remained elevated years after employment, suggesting that 
plasma indium levels reflect long-term exposure [Hoet et al., 2012]. In a larger study, air 
sampling results from eight areas did not explain observed variations in radiographic 
abnormalities among workers [Chonan et al., 2007].
Effective mitigation of workplace exposures requires health-based exposure limits to target 
controls. If indium concentrations in blood matrices reflect historical, rather than current 
exposures, then use of these biological exposure metrics for workplace exposure 
management has practical limitations. For instance, a worker’s elevated plasma indium 
concentration may either reflect ongoing exposure that needs to be addressed, or the legacy 
of working under different conditions than currently in place. As such, to identify and 
prioritize exposure control measures and for proper risk assessment to develop a protective 
exposure limit, an understanding of the direct relationship between exposure metrics and 
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health outcomes is critical. However, to date, airborne exposure data to fully characterize 
exposure-related risk for workers in the ITO industry have been unavailable.
We sought to better understand the relationships among indium exposure, plasma indium, 
and respiratory health at an ITO production and reclamation facility where two workers 
previously developed PAP, including one fatal case [Cummings et al., 2010]. Subsequent 
review of corporate medical surveillance data collected through 2010 revealed that 
pulmonary function abnormalities were in excess, but associations between adverse 
respiratory effects and average airborne indium concentrations were not evident using the 
facility’s available air sampling data [Cummings et al., 2013]. More recently, we found that 
plasma indium concentrations as low as 1 μg/L were associated with chest symptoms, 
decreased spirometric parameters, and increased serum biomarkers of lung disease among 
current workers [Cummings et al., 2014].
Indium lung disease primarily involves the alveolar or deep region of the lung [Nagano et 
al., 2011a,b; Cummings et al., 2012]. Thus, we hypothesized that particles with a mass 
median aerodynamic diameter less than 4 μm, which can penetrate into the alveolar region 
when inhaled, would be most biologically relevant. We therefore focused our exposure 
characterization on the respirable fraction of airborne particles.
 MATERIALS AND METHODS
 Study Design and Data Collection
The study population consisted of 87 (94%) current ITO facility workers, with median age 
of 44 years, median facility tenure of 1.9 years, and median plasma indium of 1.0 μg/L in 
July 2012. Approximately three-quarters worked in production areas (production or 
production support positions) and the remainder worked in laboratories or offices. The 
participants’ respiratory health has been described previously and was notable for few 
clinically significant abnormalities [Cummings et al., 2014]. An additional three workers 
contributed to the exposure assessment (described below) but did not participate in the 
study’s health component.
Exposure assessment was conducted at the facility over 2 weeks in June and September 
2012. We collected full- or multi-shift (range: 6–22 hr duration) personal samples to assess 
exposures to respirable indium. Respirable samples were collected at 4.2 Lpm using the 
GK2.69 cyclone (BGI, Inc., Waltham, MA) mounted onto two-piece, 37-mm cassette 
samplers loaded with 37-mm, 5-μm pore size polyvinyl chloride filters. Where personal 
sampling was not feasible, general area (GA) multi-shift air respirable cyclone samples were 
collected instead. A total of 110 personal respirable samples were collected from 49 workers 
(46 of whom participated in the study’s health component) for all jobs except for 
administrative (office) workers; one GA respirable sample was collected from the 
administrative office area.
Air samples were analyzed for indium by inductively coupled plasma atomic emission 
spectrometry (ICP-AES) using NIOSH Method 7303 [NIOSH, 2003], with a limit of 
detection (LOD) of 0.375 μg/sample and limit of quantification (LOQ) of 1.25 μg/sample.
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 Statistical Analyses
A substitution method was used to replace measurements below the LOD with a value of 
LOD/2, as the number of LOD measurements was small [Lubin et al., 2004]. Specifically, 
none of the respirable indium samples and four of the plasma indium samples had 
measurements below the LOD.
All personal samples for respirable indium were summarized for each job and department 
using the arithmetic mean (specifically, the minimum variance unbiased estimator [MVUE]). 
The arithmetic mean was used in this calculation as it is the desired measure of central 
tendency for estimating cumulative exposure [Smith, 1992], and the MVUE is the preferred 
estimator of the arithmetic mean when the data are lognormally distributed [Mulhausen and 
Damiano, 1998]. The job-specific mean was then assigned to each participant with that 
current job to obtain a metric of current respirable indium exposure (hereafter, “current 
exposure”). Administrative (office) workers were assigned the GA sample concentration. To 
calculate a metric of cumulative respirable indium exposure (hereafter, “cumulative 
exposure”), the current exposures were assigned to jobs in each worker’s work history 
regardless of calendar time, as detailed historical information on workplace conditions, 
processes, and representative historical exposure estimates were not available to assess or 
account for differences in exposure over time. The exposure associated with each job in the 
work history was then multiplied by the duration (in years) that the job was performed and 
summed across all jobs held to obtain cumulative exposure for each worker.
We examined correlations among the exposure variables and plasma indium using 
Spearman’s rank correlation coefficient. In addition, we used logistic, linear, and restricted 
cubic spline [Desquilbet and Mariotti, 2010] regression models to assess the relationship 
between exposure variables and plasma indium and health outcomes. In the logistic and 
linear regression models, we used the natural log of exposure variables to account for non-
linear relationships. Health outcomes consisted of respiratory symptoms as reported on the 
questionnaire, lung function test results, and KL-6 and SP-D results [Cummings et al., 
2014].
For spline regression models with cumulative exposure as the predictor variable, we used the 
study participants’ lowest cumulative exposures (≤0.44 μg-yr/m3; n =5 [6%]) as the 
reference; all were administrative (office) workers. We predicted health outcomes associated 
with specific values of cumulative exposure of interest, for example, the cumulative 
exposure value of 12 μg-yr/m3 associated with working lifetime exposure (40 years) at the 
Japanese respirable exposure limit of 0.3 μg/m3 [MHLW, 2010], the median cumulative 
exposure value, and the lowest cumulative exposure values to have statistically significant 
relationships with the outcome variables.
Final models were adjusted for cigarette smoking status (current/former/never) and age 
(years). Age was not included as a covariate in models of percent predicted values of lung 
function parameters, as the percent predicted values already account for age. We included 
facility tenure (dichotomized at the median value) as a covariate in models of current 
exposure. Past work with asbestos, silica, or other lung hazards was not associated with 
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health outcomes or plasma indium in simple analyses, and thus was not included as a 
covariate [Cummings et al., 2014].
Statistical analyses were conducted using SAS software version 9.3 and JMP software 
version 10.0.1 (SAS Institute, Inc., Cary, NC). We considered two-sided P values ≤0.05 to be 
statistically significant.
 RESULTS
A summary of the air samples collected are presented in Table I, stratified by department. 
The mean exposures were highest in the reclaim, ITO, refinery, and rotary grinding 
departments, and lowest in the administrative, shipping and receiving, and the quality 
control laboratory areas. Within departments, exposures were highly variable, often ranging 
by one to two orders of magnitude because of the differences in jobs and tasks performed 
within the departments. All measurements were greater than 0.3 μg/m3, which is the 
Japanese respirable indium standard. A large fraction (50/69; 72%) of the measurements 
collected in the production departments exceeded 10 μg/m3, which represents the Japanese 
target concentration requiring immediate actions to be taken to reduce exposures.
The current and cumulative exposures for the study participants ranged from 0.4 to 108 
μg/m3 and 0.4 to 923 μg-yr/m3, respectively. Correlations between plasma indium and 
current (rs = 0.54) and cumulative (rs = 0.78) exposure variables were evident when plotted 
on a log scale (Fig. 1). This pattern also was seen for participants with tenure ≥1.9 years (rs 
= 0.53 for current exposure and rs = 0.72 for cumulative exposure). For participants with 
tenure <1.9 years, the correlation between plasma indium and respirable indium was similar 
for current (rs = 0.74) and cumulative (rs = 0.72) exposure. For all participants, a significant 
relationship was observed between log-transformed plasma indium and log-transformed 
cumulative indium exposure using a simple regression model, which explained 60% of the 
variation in plasma indium (equation: Ln [Plasma Indium] =−2.35 +0.662*Ln [Cumulative 
Indium]).
In adjusted logistic and linear regression models, associations were observed between health 
outcomes and the exposure variables. KL-6 (U/ml) was associated with logged current 
exposure (β coefficient =118; 95%CI =64.9–172). Dyspnea, spirometric abnormality, low 
alveolar volume, percent predicted forced expiratory volume in 1 s (FEV1), percent 
predicted forced vital capacity (FVC), KL-6, and SP-D (ng/ml) were each associated with 
logged cumulative exposure (Table II). Associations between sputum production, chest 
tightness, low diffusing capacity, FEV1/FVC ratio, and logged cumulative exposure did not 
reach statistical significance (Table II).
Adjusted spline regression demonstrated statistically significant overall associations between 
all continuous health outcomes shown in Figure 2 and unlogged cumulative exposure. The 
relationships were significantly non-linear by the Wald test for percent predicted FEV1, 
FEV1/FVC ratio, and KL-6, but not for percent predicted FVC, and SP-D (Fig. 2). The 
shapes of the exposure-response curves for all of these continuous health outcomes showed 
steeper slopes at lower values of cumulative exposure and flatter slopes at higher cumulative 
Cummings et al. Page 5
Am J Ind Med. Author manuscript; available in PMC 2016 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
exposure values. Log-transformation of cumulative exposure resulted in some linearization 
of the associations for percent predicted FEV1, FEV1/FVC ratio, and KL-6, but upon 
graphical inspection, the curves looked non-linear, albeit not statistically significant (data 
not shown). The estimated percent predicted FEV1, percent predicted FVC, and FEV1/FVC 
ratio decreased, and the estimated KL-6 and SP-D increased relative to the corresponding 
values for the reference group’s cumulative exposure value of ≤0.44 μg-yr/m3. Significant 
differences were seen for percent predicted FEV1 starting at a cumulative exposure of 22 μg-
yr/m3, for FEV1/FVC ratio at 30 μg-yr/m3, for KL-6 at 63 μg-yr/m3, for percent predicted 
FVC at 240 μg-yr/m3, and for SP-D at 232 μg-yr/m3 (Table III).
Nearly half (46%) of participants had cumulative exposure levels greater than 22 μg-yr/m3 
(Fig. 3). If divided evenly over a 40-year working lifetime, these cumulative exposure values 
correspond to current exposures as low as 0.6 μg/m3 (for percent predicted FEV1) to 6.0 
μg/m3 (for SP-D). The majority (82%) of participants had current exposure levels greater 
than 0.6 μg/m3, and 41% had current exposure levels greater than 6.0 μg/m3 (Fig. 3).
The last three columns in Table I show the number of years it would to take to reach a 
cumulative exposure of 22 μg-yr/m3 at the mean exposure levels in each department. 
Without respiratory protection, administrative (office) workers were the only participants 
who would not reach a cumulative exposure of 22 μg-yr/m3 during a 40-year working 
lifetime. Without respiratory protection, workers in the reclaim, ITO, rotary grind, planar 
grind, and research and development departments would reach 22 μg-yr/m3 in less than 1 
year of employment. With a disposable N95 filtering-facepiece respirator (assigned 
protection factor [APF] of 10), this time period would be extended to 2.0–8.1 years. With a 
powered air-purifying respirator (APF of 25), this time period would be extended to 5.1–
20.2 years.
 DISCUSSION
At an ITO production and reclamation facility where health risks were previously 
demonstrated [Cummings et al., 2010, 2013, 2014], we found that plasma indium correlated 
well with measures of airborne respirable indium, particularly when we accounted for the 
time that workers spent in different jobs at the facility. Furthermore, associations that we 
previously reported between health outcomes and plasma indium [Cummings et al., 2014] 
were also evident between health outcomes and a cumulative indium exposure metric 
developed on the basis of air measurements. Indeed, workers with higher cumulative 
exposures had more dyspnea, lower lung function, and increased serum concentrations of the 
interstitial lung disease biomarkers KL-6 and SP-D that were not explained by age or 
smoking status. The demonstration of relationships between respirable indium exposure 
metrics and health is particularly important from a practical viewpoint because airborne 
metrics of exposure, rather than biomarkers of exposure, are measured by industrial 
hygienists in the workplace to guide controls.
To our knowledge, ours is the first study to demonstrate a relationship between 
concentrations of indium in plasma and air. Hoet et al. [2012] found no such association, but 
with only nine current workers, their study may not have had adequate power for this 
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outcome. Variations in the chemical forms of indium present in the air and the air sampling 
methods employed in the two studies may also have contributed to the different findings. 
Hoet et al. [2012] conducted their study in a facility with indium but not ITO and collected 
the inhalable fraction, while we conducted our study in an ITO production facility and used 
the respirable fraction. We found that cumulative exposure had a stronger relationship with 
plasma indium than did current exposure, which was driven by participants with longer 
tenure. This finding is consistent with prior evidence of indium compounds’ slow dissolution 
and clearance from the body. In one study, current and former workers had similar mean 
serum indium concentration (8.4 vs. 9.6 μg/L), though former workers’ indium exposure had 
ended an average of nearly 5 years before the study [Nakano et al., 2009]. Urine indium 
concentrations did not vary over the workweek or after a weekend in the study by Hoet et al. 
[2012], which is consistent with the slow dissolution of indium, and suggests the presence of 
a body burden of indium. Furthermore, in hamsters exposed to ITO or indium oxide by 
intratracheal instillation, serum indium concentration increased consistently during the 
follow-up period, up to 78 weeks after the final exposure [Tanaka et al., 2010].
Our demonstration of associations between health outcomes and airborne exposure metrics 
is also, to our knowledge, unique. We found one association with current exposure and more 
numerous associations with cumulative exposure. Notably, cumulative exposure variables 
performed quite comparably to plasma indium, identifying the same health outcomes and 
similar relational patterns [Cummings et al., 2014]. Associations with health outcomes were 
evident at cumulative exposures as low as 22 μg-yr/m3 for this short-tenure workforce. In 
calculating exposures, we did not account for participants’ use of respiratory protection, 
which was primarily task-based and thus intermittent. Use of respiratory protection likely 
reduced the actual exposures compared to the measured concentrations of indium in the air 
for some participants. Overestimation of exposure leads to underestimation of risk. Thus, 
had we been able to accurately account for the effects of respiratory protection, we expect 
that we would have found health effects at even lower levels of cumulative exposure.
We found that many production workers would reach a cumulative exposure of 22 μg-yr/m3 
in less than 1 year of employment without respiratory protection, and within a few years 
even with the use respiratory protection. The calculated times while using respiratory 
protection relied on the APF, which could overestimates the actual protective capacity of the 
respirator if it is not fitted and worn properly. Hence, it is possible that we overestimated the 
time a worker wearing respiratory protection would reach a cumulative exposure of 22 μg-
yr/m3. It is important to note that respiratory protection is the intervention choice of last 
resort and should be instituted as a temporary solution while more permanent engineering 
and administrative controls are evaluated and implemented.
Despite the relatively short tenure of the workers we studied, the associations we found are 
likely to be due to the effect of indium compounds on the lung for several reasons. First, 
they are biologically plausible, given the lung toxicity of indium oxide and ITO observed in 
animal studies [Leach et al., 1961; Lison et al., 2009; Tanaka et al., 2010; Nagano et al., 
2011a,b; Badding et al., 2015]. Second, they are consistent with the lung disease reported in 
ITO industry workers, which was notable for short latency from first exposure to diagnosis 
[Cummings et al., 2012]. Indeed, the two cases of PAP in this facility occurred within 12 
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months of hire [Cummings et al., 2010]. Third, they reflect subclinical or undiagnosed lung 
disease experienced by ITO industry workers in many other facilities worldwide [Chonan et 
al., 2007; Hamaguchi et al., 2008; Nakano et al., 2009; Liu et al., 2012; Choi et al., 2013]. 
Fourth, they were not accounted for by potential confounders such as age or smoking, which 
are known risk factors for decreased lung function. In addition, we previously showed that 
there were no associations between health outcomes and self-reported prior occupational 
exposure to asbestos, silica, or other lung hazards [Cummings et al., 2014]. Finally, although 
we could not address temporality in a cross-sectional study, a recently reported 5-year 
follow-up of indium workers found that serum indium, KL-6, and SP-D all declined to 
similar degrees with cessation or reduction of exposure [Nakano et al., 2014].
Indium and dust exposure metrics were highly correlated (rs ≥ 0.89), and results were similar 
between models of health outcomes that used respirable indium exposure and those that used 
respirable dust exposure (data not shown). These findings are not unexpected, given that 
most processes in the facility involved some form of indium. The agreement between indium 
and dust exposure metrics suggests that respirable dust concentration is a reasonable 
surrogate for respirable indium exposure in this facility. This observation has practical 
consequence, as real-time dust monitors can be used to identify high exposure tasks that 
warrant intervention. High exposure tasks may not only increase personal exposures of 
workers performing the task, but also act as a source for general area contamination and 
increase exposures for nearby tasks. Dust measurement also can be used as a surveillance 
tool to quickly, simply, and cost-efficiently identify new and developing problem situations 
that can be targeted for measurement of indium concentrations in air.
Since acquiring the facility in 2002, the owner made multiple changes intended to reduce 
workers’ exposures to indium compounds. These included ventilation improvements, 
process enclosures, and the introduction of a respiratory protection program [Cummings et 
al., 2013]. Systematic longitudinal exposure assessment was not conducted, but it is likely 
that workplace improvements that occurred over the 10 years preceding the study resulted in 
lower exposures over time, although reductions may not have been uniform throughout the 
facility. Yet without accurate representative historical exposure data, we were unable to 
account for possible secular trends in exposure when developing the cumulative exposure 
variable. Rather, this variable was based on exposures measured in 2012, adjusted only for 
time spent in a job and jobs held at the facility. To the extent that exposures in 2012 were 
lower than in years prior, the cumulative exposure that we used likely underestimated true 
cumulative exposures to some degree. While underestimation of exposure will lead to 
overestimation of risk, half of the participants had been hired in the previous 2 years and 
75% in the previous 5 years, so most participants’ experiences reflected the more recent 
conditions.
Potential indium exposures at this facility were not limited to ITO, but also included indium 
metal, indium hydroxide, indium salts, and indium oxide. The toxicity profiles of these 
compounds, though not fully elucidated, are unlikely to be the same. Available information 
indicates differential toxicity between indium oxide and ITO [Lison et al., 2009; Nagano et 
al., 2011a,b]. In an in vitro studies using eight process materials from this facility, we 
recently showed differences among the materials in terms of cell survival and viability 
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[Badding et al., 2014]. In this context, it is important to note that neither plasma indium nor 
respirable indium differentiates between the various indium compounds used at the facility. 
Rather, these are non-specific metrics that integrate information on all chemical forms of 
indium exposures, regardless of relative toxicity; thus, their use may have led to some 
exposure misclassification.
Understanding the relationship between indium exposures and respiratory health has critical 
implications for prevention of indium lung disease in current and future ITO industry 
workers. Although in estimating time to a cumulative exposure of 22 μg-yr/m3 we assumed 
risk over time was linear, follow-up will be needed to determine the long-term effects of 
exposures at the observed levels in this short-tenure workforce. Furthermore, the 
generalizability of our findings should be confirmed through study of other worker cohorts, 
such as those with longer tenure and different exposure profiles. The risks to workers 
encountering indium compounds outside of the primary ITO industry are largely unknown. 
One case of indium lung disease was reported in a Chinese mobile telephone worker who 
cleaned components of ITO thin-film production machinery by sandblasting [Xiao et al., 
2010; Cummings et al., 2012], and a recent investigation found associations between serum 
indium and KL-6 in dental technicians, solder workers, and others with indium metal 
exposure [Nakano et al., 2015], suggesting broader investigation is warranted.
 CONCLUSIONS
Among ITO production and reclamation workers, we found good correlation between 
plasma indium concentrations and respirable indium exposures. Current and cumulative 
indium exposure variables had similar correlations with plasma indium for workers with 
facility tenure <1.9 years, while cumulative indium exposure variables were better correlated 
with plasma indium for those with tenure ≥1.9 years and for the group as a whole. 
Cumulative respirable indium exposures were associated with more dyspnea, lower 
spirometric parameters, and higher serum biomarkers of interstitial lung disease, reflecting 
previously reported associations between plasma indium concentration and health outcomes. 
These findings indicate adverse health effects with relatively low respirable exposure to 
indium compounds and support efforts aimed at further exposure reduction in the ITO 
industry.
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FIGURE 1. 
Correlation between current (left) and cumulative (right) indium exposure and plasma 
indium concentration among workers at an indium-tin oxide facility. Current exposure 
values were assigned on the basis of indium concentrations measured for a participant’s 
current job; cumulative exposure values account for the time a participant spent in each job 
during employment at the facility. Both air and plasma values plotted using a log scale. The 
relationship between log transformed plasma indium and log transformed cumulative indium 
was given by the following equation: Ln (Plasma Indium) =−2.35 +0.662*Ln (Cumulative 
Indium), R2 =0.60, P <0.05. rs = Spearman’s rank correlation coefficient.
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FIGURE 2. 
Restricted cubic splines show non-linear relationships between spirometric parameters (top) 
and serum biomarkers of interstitial lung disease (bottom) on the vertical axis and 
cumulative indium exposure on the horizontal axis, adjusted for smoking status (current/
former/never). Splines for FEV1/FVC ratio, KL-6, and SP-D are also adjusted for age 
(years). Cumulative indium exposure values account for the time a participant spent in each 
job during employment at the facility. The splines model the difference in the value of the 
health outcome at any given value of cumulative exposure compared to a cumulative indium 
exposure value of 0.44 μg/L. Individual cumulative indium exposure values (observations) 
are indicated by the crosses above the x-axis. FEV1, forced expiratory volume in 1s; FVC, 
forced vital capacity; KL, Krebs von den Lungen; SP-D, surfactant protein-D; CL, 
confidence limit; Obs, observation.
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FIGURE 3. 
Histograms showing the distributions of current (left) and cumulative (right) respirable 
indium exposures of the study participants. Reference lines show the percent of participants 
with exposures greater than those associated with changes in health outcomes. For 
cumulative exposure, reference lines indicate 46% >22 μg-years/m3 (decline in percent 
predicted FEV1); 43% >30 μg-years/m3 (decline in FEV1/FVC ratio); 36% >63 μg-years/m3 
(increase in KL-6); 9% >232 μg-years/m3 (decline in percent predicted FVC); and 8% >240 
μg-years/m3 (increase in SP-D). For current exposure, reference lines indicate 82% >0.6 
μg/m3; 82% >0.8 μg/m3; 82% >1.6 μg/m3; 41% >5.8 μg/m3; and 41% >6 μg/m3. These 
values were chosen because they reflect the current exposures that would lead to cumulative 
exposures of 22, 30, 63, 232, and 240 μg-years/m3 after 40 years.
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TABLE II
Results of Adjusted Models of Relationship Between Health Outcomes and Log-Transformed Cumulative 
Indium Exposure for Workers at an Indium-Tin Oxide (ITO) Facility
Health outcome
Value
OR (95%CI)a
Coughb 1.0 (0.7; 1.3)
Sputum productionb 1.4 (0.9; 2.5)
Dyspneab 1.5 (1.0; 2.4)
Wheezeb 1.0 (0.7; 1.3)
Chest tightnessb 1.3 (0.9; 2.0)
Spirometric abnormalityc 1.5 (1.0; 2.4)
Low DLCOc 1.5 (0.9; 2.7)
Low VAc 1.6 (1.0; 2.7)
βcoefficient (95%CI)a
FEV1 % predicted c −2.7 (−4.3; −1.1)
FVC % predictedc −1.9 (−3.5; −0.3)
FEV1/FVC % b −0.7 (−1.5; 0.1)
DLCO % predictedc −0.1 (−1.9; 1.7)
VA % predicted c −0.4 (−1.8; 1.0)
KL-6 (U/ml)b 107 (61.0; 154)
SP-D (ng/ml)b 19.1 (4.2; 34.1)
OR, odds ratio; CI, confidence interval; DLCO, diffusing capacity of the lungs for carbon monoxide; VA, alveolar volume; FEV1, forced 
expiratory volume in 1s; FVC, forced vital capacity; KL, Krebs von den Lungen; SP-D, surfactant protein-D.
aOdds ratios are presented for categorical outcomes and β coefficients for continuous outcomes. Significant (P ≤0.05) differences are in bold.
b
Model adjusted for age and smoking status (current/former/never).
c
Model adjusted for smoking status (current/former/never).
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